People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Anacor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $19.4M | $83.6M | 2013 |
Lee Zane at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lee Zane on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Perry | 1 | 11 |
| Mark Leschly | 1 | 9 |
| Paul Klingenstein | 1 | 6 |
| William Rieflin | 1 | 4 |
| Anders Hove | 1 | 4 |
| Geoffrey Parker | 1 | 3 |
| Richard Markham | 1 | 3 |
| Paul Berns | 1 | 3 |
| Sanjay Chanda | 1 | 2 |
| Zhi Hong | 1 | 2 |
| Jacob Plattner | 1 | 1 |
| Kirk Maples | 1 | 1 |
| Lucy Shapiro | 1 | 1 |
| Irwin Heyman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.